Evidence map›Paper›PMID 32738510›Full record

ArticleNutrition (Burbank, Los Angeles County, Calif.)2021

Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?

Raquel S Torrinhas, Philip C Calder, Gabriela O Lemos, Dan L Waitzberg

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrition (Burbank, Los Angeles County, Calif.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. COVID-19 and cancer: start the resolution!Cancer metastasis reviews · 2022
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Raquel S TorrinhasDepartment of Gastroenterology, Faculty of Medicine, Laboratory of Nutrition and Metabolic Surgery, University of São Paulo, São Paulo, Brazil. Electronic address: rtorrinhas@gmail.com.
Philip C CalderHuman Development & Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; NIHR Southampton Biomedical Research Center, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom.
Gabriela O LemosDepartment of Gastroenterology, Faculty of Medicine, Laboratory of Nutrition and Metabolic Surgery, University of São Paulo, São Paulo, Brazil.
Dan L WaitzbergDepartment of Gastroenterology, Faculty of Medicine, Laboratory of Nutrition and Metabolic Surgery, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new coronavirus associated with severe acute respiratory syndrome (SARS-CoV-2), surprisingly, does not affect only the lungs. The severe response to SARS-CoV-2 appears to include a "cytokine storm," which indicates a state of hyperinflammation and subsequent dysfunction of multiple organs and tissues in the most severe cases. This could be the reason why populations at the highest risk for death from the SARS-CoV-2 infection-induced disease (coronavirus disease 2019 [COVID-19]) are those suffering from chronic low-grade inflammation, but prone to hyperinflammation. This includes individuals of advanced age and those with obesity, type 2 diabetes, hypertension, and metabolic syndrome. Inflammation resolution is strongly dependent on lipid mediators, the specialized pro-resolution mediators (SPMs). ω-3 polyunsaturated fatty acids (ω-3 PUFAs) are precursors of very potent SPMs, including resolvins, protectins, and maresins. Additionally, they are associated with a less aggressive inflammatory initiation, after competing with ω-6 fatty acids for eicosanoid synthesis. Therefore, it makes sense to consider the use of ω-3 PUFAs for clinical management of COVID-19 patients. ω-3 PUFAs may be given by oral, enteral, or parenteral routes; however, the parenteral route favors faster incorporation into plasma phospholipids, blood cells, and tissues. Here, we discuss these aspects to propose the parenteral infusion of ω-3 PUFAs as adjuvant immunopharmacotherapy for hospitalized patients with COVID-19.

Indexed as

COVID-19 Drug TreatmentChemotherapy, AdjuvantCOVID-19Cytokine Release SyndromeFatty Acids, Omega-3Fish OilsHumansInflammationInfusions, ParenteralModels, BiologicalNutritional Physiological PhenomenaPandemicsSARS-CoV-2Fatty Acids, Omega-3Fish OilsCOVID-19HyperinflammationParenteral fish oilResolution of inflammationSpecialized pro-resolving mediators

Identifiers

PMID32738510
PMCPMC7836308
OpenAlexW3036902958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.